It operates in the world of money and finance. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 30% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
The stock trades 59% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 35% a year on average.
Sales run at $210.1M a year. A small number, but proof the product has real buyers.
A loss of $83.3M against $210.1M in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.32. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
On our five-subject report card, IPAXW sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: IPAXW is a high-risk stock — not yet profitable, and its future rides on its product catching on.